Safety and Tolerability of POD-DHE (INP104) in Migraine (STOP 301)
Open-label Study of Safety and Tolerability of Chronic Intermittent Usage for 24 or 52 Weeks of Intranasal Dihydroergotamine Mesylate (DHE) Administered Using the I123 Precision Olfactory Delivery (POD®) Device [INP104, POD-DHE] in Patients With Migraine Headache
Study Overview
Status
Status
Conditions
Conditions
Intervention / Treatment
Intervention / Treatment
Detailed Description
Study Type
Study Type
Enrollment (Actual)
Enrollment
Phase
Phase
- Phase 3
Contacts and Locations
Study Locations
-
-
Alabama
-
Birmingham, Alabama, United States, 35211
- Synexus - Clinical Research Advantage, Inc. - Simon Williamson Clinical, PC., 832 Princeton Avenue Southwest
-
Birmingham, Alabama, United States, 35235
- Alabama Clinical Therapeutics, LLC., 52 Medical Park East Drive, Suite 203
-
-
Arizona
-
Chandler, Arizona, United States, 85224
- Synexus - Radiant Research, Inc. - Phoenix SE, 2081 West Frye Road
-
Phoenix, Arizona, United States, 85020
- Synexus - Clinical Research Advantage, Inc., Central Phoenix Medical Clinic, LLC., 7600 North 15th Street, Suite 191
-
-
California
-
Long Beach, California, United States, 90806
- Collaborative Neuroscience Network, LLC., 2600 Redondo Avenue, Suite 415
-
Oceanside, California, United States, 92056
- Excell Research, 3998 Vista Way
-
-
Colorado
-
Colorado Springs, Colorado, United States, 80909
- Synexus - Clinical Research Advantage, Inc. - Colorado Springs Family Practice, 2960 North Circle Drive, Suite 200
-
-
Florida
-
Jacksonville, Florida, United States, 32256
- Clinical Neuroscience Solutions, Inc., 5200 Belfort Road, Suite 420
-
Orlando, Florida, United States, 32801
- Clinical Neuroscience Solutions, Inc., 618 East South Street, Suite 100
-
Tampa, Florida, United States, 33634
- Meridien Research - Tampa, 5411 Beaumont Center Boulevard, Suite 760
-
West Palm Beach, Florida, United States, 33407
- ENT Associates of South Florida, 4631 North Congress Avenue, Suite 200
-
Winter Haven, Florida, United States, 33880
- Clinical Research of Central Florida, 500 East Central Avenue
-
-
Georgia
-
Atlanta, Georgia, United States, 30328
- Synexus - Atlanta, 6065 Roswell Road, Suite 820
-
-
Illinois
-
Chicago, Illinois, United States, 60607
- Cedar Crosse Research Center, 800 South Wells Street, Suite M-15
-
-
Indiana
-
Evansville, Indiana, United States, 47714
- Synexus - Clinical Research Advantage, Inc. - Allaw, 958C S. Kenmore Drive
-
-
Kentucky
-
Lexington, Kentucky, United States, 40509
- Central Kentucky Research Associates, Inc., 3475 Richmond Road, 3rd Floor
-
-
Louisiana
-
Marrero, Louisiana, United States, 70072
- Tandem Clinical Research, LLC., 1111 Medical Center Boulevard, N513
-
-
Minnesota
-
Edina, Minnesota, United States, 55435
- Synexus - Radiant Research, Inc., - Minneapolis, 7250 France Avenue South, Suite 417
-
-
Missouri
-
Saint Louis, Missouri, United States, 63141
- Synexus - Radiant Research, Inc. - St. Louis, 675 Old Ballas Road, Suite 103
-
Saint Peters, Missouri, United States, 63303
- StudyMetrix Research, LLC., 3862 Mexico Road
-
-
Nebraska
-
Omaha, Nebraska, United States, 68144
- Synexus - Clinical Research Advantage, Inc. - Omaha, 11020 Prairie Brook Road
-
-
Nevada
-
Henderson, Nevada, United States, 89052
- Synexus - Clinical Research Advantage, Inc. - Rita B. Chuang, MD, LLC., 2629 West Horizon Ridge Parkway, Suite 130
-
-
New Jersey
-
Berlin, New Jersey, United States, 08009
- Hassman Research Institute, 175 Cross Keys Road, Suite 300B
-
-
New York
-
Brooklyn, New York, United States, 11229
- Integrative Clinical Trials, 3288 Ocean Avenue, Unit # MO
-
Jamaica, New York, United States, 11432
- CNS Research Science, Inc., 80-15 164th Street
-
-
Ohio
-
Columbus, Ohio, United States, 43213
- Aventiv Research, 99 North Brice Road, Suite 260
-
-
Oklahoma
-
Edmond, Oklahoma, United States, 73034
- OK Clinical Research, LLC., 120 North Bryant Avenue, Suite A5
-
-
Oregon
-
Portland, Oregon, United States, 97210
- Summit Research Network Oregon, 2701 North West Vaughn Street, Suite 350
-
-
Pennsylvania
-
Smithfield, Pennsylvania, United States, 15478
- Frontier Clinical Research, LLC., 100 Ridge View Drive, Unit 4
-
-
South Carolina
-
North Charleston, South Carolina, United States, 29406
- Coastal Carolina Research Center, 9279 Medical Plaza Drive, Suite B2
-
-
Tennessee
-
Chattanooga, Tennessee, United States, 37421
- MR - ClinSearch, LLC., 6035 Shallowford Road, Suite 109
-
Memphis, Tennessee, United States, 38119
- Clinical Neuroscience Solutions, Inc., 6401 Poplar Avenue, Suite 420
-
-
Texas
-
Austin, Texas, United States, 78731
- FutureSearch Trials of Neurology, 5508 Parkcrest Drive, Suite 300
-
Plano, Texas, United States, 75093
- Synexus - Clinical Research Advantage, Inc. - Plano Internal Medicine Associates, PA., 6300 West Parker Road, Suite 220
-
-
Utah
-
Murray, Utah, United States, 84123
- Synexus - Radiant Research, Inc. - Salt Lake City, 5251 South Green Street, Suite 300B
-
-
Virginia
-
Richmond, Virginia, United States, 23294
- National Clinical Research, Inc., 2809 Emerywood Parkway, Suite 140
-
-
Participation Criteria
Eligibility Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria:
- Documented diagnosis of migraine with or without aura, with at least 2 attacks per month for the previous 6 months.
- Participants must be in good general health, with no significant medical history (excluding migraine).
- Participants must have the ability and willingness to attend the necessary visits at the study center.
- Participants must be able to provide the written informed consent prior to entry into the study.
- Women of childbearing potential must agree to use adequate contraception (as defined in the protocol and by study personnel) during the study and for 30 days after the last dose fo the study drug.
- Male participants and their partners must agree to use effective contraception (as defined in the protocol and by study personnel) during the study and for 30 days after the last dose of the study drug. Male participants should also refrain from sperm donation for 30 days after study completion.
Exclusion Criteria:
- Subjects with trigeminal autonomic cephalalgias (including cluster headache, hemicrania syndromes and short-lasting unilateral, neuralgiform headache attacks with conjunctival injection and tearing), hemiplegic migraine, or migraine with brainstem aura (previously referred to as basilar migraines).
- Subjects with chronic migraines, medication overuse headache or other chronic headache syndromes.
- Subjects with ischemic heart disease or subjects with clinical symptoms or findings consistent with coronary artery vasospasm, including Prinzmetal's variant angina.
- Subjects with significant risk factors for coronary artery disease (CAD) including current use of nicotine-containing products, medical history of diabetes, uncontrolled hypertension (high blood pressure), known peripheral arterial disease, Raynaud's phenomenon, sepsis or vascular surgery (within 3 months prior to study start), or severely impaired hepatic or renal (kidney) function.
- Subjects with recurrent sinusitis or epistaxis.
- Subjects with a history or presence of alcoholism or drug abuse within 2 years prior to first study drug administration.
- Women who are pregnant, or planning to get pregnant, or who are lactating while participating in the study.
- Use of any medications prohibited by protocol.
- Use of >12 days per month of triptan or ergot-based medication in the 2 months prior to screening.
Other protocol-defined inclusion/exclusion criteria may apply.
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: N/A
- Interventional Model: Single Group Assignment
- Masking: None (Open Label)
Number of Arms
Arms and Interventions
Participant Group / ArmParticipant Group / Arm |
Intervention / TreatmentIntervention / Treatment |
|---|---|
|
Experimental: INP104
24-week treatment period for all participants followed by a 28-week treatment extension period for a subset of participants
|
No more than 2 doses within 24 hours, 3 doses within 7 days.
1.45 mg in a divided dose, one actuation per nostril.
Other Names:
|
What is the study measuring?
Primary Outcome Measures
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Number of Participants With Serious Adverse Events (SAEs)
Time Frame: From study enrollment up to Week 26 (for the 24-Week Treatment Group) and up to Week 54 (for the 52-WeekTreatment Group)
|
Number of participants with Serious Adverse Events (SAEs) whether or not related to study drug.
|
From study enrollment up to Week 26 (for the 24-Week Treatment Group) and up to Week 54 (for the 52-WeekTreatment Group)
|
|
Number of Participants With Non-serious Treatment Emergent Adverse Events (AEs)
Time Frame: From first use of INP104 up to Week 26 (for the 24-Week Treatment Group) and up to Week 54 (for the 52-WeekTreatment Group)
|
Number of participants with non-serious treatment emergent adverse events (AEs), whether or not related to study drug.
|
From first use of INP104 up to Week 26 (for the 24-Week Treatment Group) and up to Week 54 (for the 52-WeekTreatment Group)
|
|
Change in Nasal Mucosa
Time Frame: Baseline up to Week 24 (for the 24-Week Treatment Group) and Baseline up to Week 52 (for the 52-WeekTreatment Group)
|
Mean change from baseline in Quantitative Scoring Scale for Evaluation of the Nasal Mucosa (QSS-NM) score, reported at designated intervals on study.
This scale was scored by otolaryngologists during routine endoscopy of the upper nasal cavity of participants.
A minimum score of 0 means no issues were detected.
A maximum score of 34 indicates severe issues (worse outcome).
|
Baseline up to Week 24 (for the 24-Week Treatment Group) and Baseline up to Week 52 (for the 52-WeekTreatment Group)
|
|
Change in Olfactory Function
Time Frame: Baseline up to Week 24 (for the 24-Week Treatment Group) and Baseline up to Week 52 (for the 52-WeekTreatment Group)
|
Mean change from baseline in olfactory function score, assessed using the University of Pennsylvania Smell Identification Test (UPSIT), and reported at designated intervals on study.
The UPSIT is a 40 question scratch and sniff test of olfactory function.
The minimum score of 0 indicates worst olfactory function, and the maximum score of 40 indicates the highest level of olfactory function detectable by the test.
|
Baseline up to Week 24 (for the 24-Week Treatment Group) and Baseline up to Week 52 (for the 52-WeekTreatment Group)
|
Collaborators and Investigators
Sponsor
Sponsor
Publications and helpful links
Helpful Links
Study record dates
Study Major Dates
Study Start (Actual)
Study Start
Primary Completion (Actual)
Primary Completion
Study Completion (Actual)
Study Completion
Study Registration Dates
First Submitted
First Submitted
First Submitted That Met QC Criteria
First Submitted That Met QC Criteria
First Posted (Actual)
First Posted
Study Record Updates
Last Update Posted (Actual)
Last Update Posted
Last Update Submitted That Met QC Criteria
Last Update Submitted That Met QC Criteria
Last Verified
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
- Brain Diseases
- Central Nervous System Diseases
- Nervous System Diseases
- Pain
- Neurologic Manifestations
- Headache Disorders, Primary
- Headache Disorders
- Migraine Disorders
- Headache
- Physiological Effects of Drugs
- Neurotransmitter Agents
- Molecular Mechanisms of Pharmacological Action
- Peripheral Nervous System Agents
- Analgesics
- Sensory System Agents
- Analgesics, Non-Narcotic
- Dopamine Agonists
- Dopamine Agents
- Vasoconstrictor Agents
- Dihydroergotamine
Other Study ID Numbers
Other Study ID Numbers
- INP104-301
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.